The efficacy of ganciclovir combined with spleen aminopeptide in treating infectious mononucleosis and its impact on the immune function of diseased children
10.13431/j.cnki.immunol.j.20250053
- VernacularTitle:更昔洛韦联合脾氨肽治疗传染性单核细胞增多症的疗效及对患儿免疫功能的影响
- Author:
Youjia SUN
1
;
Guijuan ZHOU
1
;
Yuee JIA
1
;
Haixia LI
1
;
Xue FANG
1
Author Information
1. 066200,秦皇岛市工人医院儿科
- Publication Type:Journal Article
- Keywords:
Ganciclovir;
Spleen aminopeptide;
Infectious mononucleosis;
Immune function
- From:
Immunological Journal
2025;41(5):356-361
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of ganciclovir combined with spleen aminopeptide in treating infectious mononucleosis(IM)and its impact on the immune function of diseased children.Methods Totally 120 diseased children with IM accepted by our hospital from February 2022 to August 2024 were stochastically assigned into a treatment group and a monotherapy group.The monotherapy group received treatment with ganciclovir,while the treatment group received treatment with spleen aminopeptide in addition to the monotherapy group.The efficacy,symptom improvement time,serum inflammatory factors,immune indicators,and biochemical indicators before and after treatment were compared between the two groups.Results The efficacy of the treatment group was better than that of the monotherapy group,and the symptom relief time was shorter than that of the monotherapy group(P＜0.05).After treatment,the serum amyloid A,TNF-α,IL-6,procalcitonin,CD3+T,CD8+T,lactate dehydrogenase,alanine aminotransferase,EBV-DNA,creatine kinase,and white blood cell count in both groups decreased,while CD4+T and CD4+T/CD8+T increased.The amplitude of the treatment group was greater than that of the monotherapy group(P＜0.05).Conclusion The combination of ganciclovir and spleen aminopeptide in treating IM is beneficial for enhancing the immune function of T lymphocytes of diseased children,alleviating inflammatory reactions,improving biochemical indicators,and enhancing efficacy.
